Dapagliflozin-Induced Vulvovaginitis in an Atopic Patient with Type 2 Diabetes Mellitus

Tip 2 Diabetes Mellituslu Atopik Hastada Dapagliflozin Kaynaklı Vulvovajinit

Narin Nasiroğlu İmga, Merve Çatak, Dilek Berker

Saçılık Bilimleri University Ankara Numune Education and Research Hospital, Department of Endocrinology and Metabolism, Ankara

Case Report

TurkJEndocrinolMetab2018;22:213-216

Abstract

Dapagliflozin, an oral anti-diabetic agent, is a recently discovered sodium-glucose co-transporter receptor-2 inhibitor, which improves glycemic control by facilitating the renal excretion of glucose. Urinary and genital tract infections are common in type-2 diabetes mellitus. Vulvovaginal candidiasis is an infection of the vaginal vestibular area. We present a case of vulvovaginal candidiasis associated with the use of dapagliflozin. A 48-years-old female patient having type-2 diabetes mellitus for the past eight years was admitted to our outpatient clinic. Her medical history was remarkable for atopic dermatitis. She was using metformin and sulfonylurea. Her hemoglobin A1c was 7.8%. A daily dose of 10 mg dapagliflozin was added to her treatment. On the 12th day of dapagliflozin therapy, she noted vulvovaginal pruritus, which was reported three days later, after the symptoms worsened. Physical examination revealed widespread erythema on vulvar, vaginal, and perineal regions of the genitourinary area. The vaginal culture was positive for *Candida albicans*. Thus, the patient was diagnosed with vulvovaginal candidiasis. Treatment included topical clotrimazole. Three days later, after symptoms improved, dapagliflozin was discontinued. This led to the regression in signs and symptoms of vulvovaginal candidiasis. Hence, an appropriate diagnosis and management of vulvovaginal candidiasis were essential to provide optimal genital and metabolic health. We believe that this case will be highly relevant among atopic patients at potential risk of vulvovaginal candidiasis and recommend that a drug withdrawal may be considered in such patients.

Keywords: Type 2 DM; dapagliflozin; vulvovaginitis

Anahtar kelimeler: Tip 2 DM; dapagliflozin; vulvovajinit

Introduction

The prevalence of type-2 diabetes mellitus (T2DM) is ever-increasing, and it presently affects at least 285 million people worldwide (1). The first line of treatment for patients with T2DM is modification of the lifestyle, including diet, exercise, and weight reduction as required (2). The development of new therapeutic agents for the treatment of T2DM is continuously undertaken to achieve optimum HbA1C levels. New drugs with...
different mechanisms of managing various conditions in the etiopathogenesis of diabetes are still being developed. The sodium-glucose co-transporter receptor-2 (SGLT2) inhibitors are recently discovered oral antidiabetic (OAD) agents that improve glycemic control by facilitating the renal excretion of glucose. SGLT2 inhibitors are known to have benefits such as weight loss, reduction in systolic blood pressure, and low hypoglycemic risk. However, they are also known to cause urinary and genital tract infections more commonly than other antidiabetic agents (3).

Vulvovaginitis (VV) is a genital infection which could be a complication of T2DM. Vulvovaginal candidiasis (VVC) is an infection of the vaginal vestibular area, which can also spread to the outer parts of the labia minora and labia majora, and the intercrural and perineal regions (4). Herein we present a case of VVC associated with the use of dapagliflozin.

Case Report

A 48-year-old woman with T2DM for the past eight years was admitted to the endocrinology clinic for routine follow-up. Her body mass index was 33.7 kg/m². Her past medical history was remarkable for atopic dermatitis since childhood but she was having arterial hypertension for five years. She had been using metformin and sulfonylurea to manage T2DM, while her blood pressure was controlled with 80 mg valsartan daily. She was a non-smoker but had a positive family history for T2DM. Her initial laboratory results were as follows: fasting plasma glucose = 131 mg/dL, HbA1c = 7.5%, low-density lipoprotein (LDL) = 101 mg/dL, alanine aminotransferase (ALT) = 21 U/L, creatinine = 0.72 mg/dL, GFR > 60 mL/min, and spot urinary microalbumin/creatinine ratio = 28.8 µg/mg, TSH: 2.3 µU/mL (normal range: 0.27-4.2), free T4: 1.1 ng/dL (normal range: 0.87-1.7). White blood count results were 7800 10³/µL. A daily dose of 10 mg dapagliflozin was added to her treatment schedule. On the 12th day of dapagliflozin therapy, she noted vulvovaginal pruritus. Three days later, she complained of increased severity of symptoms and was admitted to our clinic for further management. Physical examination revealed widespread erythema on vulvar, vaginal, and perineal regions of the genitourinary area. Spot urine glucose excretion level was not checked at fasting, but the urinalysis showed glucose to be 1+. Four leukocytes and 15 erythrocytes per high power objective field were detected in the urine sediment through microscopy. Although the urine culture was negative, the vaginal culture was positive for Candida albicans. Thus, the patient was diagnosed with VVC. The blood sedimentation rate was normal and leucocytosis was not observed, but C-Reactive Protein (CRP) level was observed to be 30 mg/L (normal range 0–5 mg/L). For the treatment of VVC, topical application of clotrimazole cream was prescribed. Dapagliflozin and metformin treatment was continued. However, upon worsening of the clinical manifestations three days later, dapagliflozin was discontinued, the patient was switched to vildagliptin, and topical clotrimazole therapy was continued. The symptoms of VVC regressed after two days, and the patient had no further complaints.

Discussion

Dapagliflozin is an SGLT2 inhibitor which can be used singly or as a part of combined therapy in patients whose hyperglycemia is ineffectively controlled by other antidiabetic medications. It is proven that glucosuria facilitates the growth of bacteria and increases their adherence to the uroepithelium and vaginal epithelial cells, which might be linked with the increased incidence of genital infections (5).

It is known that SGLT2 inhibitors are insulin-independent glucose-lowering agents which function by inhibiting GLUT-1 and GLUT-2 renal glucose transporters (6). Dapagliflozin provides moderate weight loss and blood pressure reduction in T2DM (7). The advantages are a low risk of hypoglycemia, weight loss, decreased blood pressure, and association with lower incidences of cardiovascular failure and mortality in patients with cardiovascular disease. Disadvantages include genitourinary infections, polyuria, volume depletion, and transient elevation of creatinine levels. Urinary tract infections can progress to urosepsis and pyelonephritis (8).

Signs, symptoms, and events suggestive of genital infection were reported in ≥1% of women being treated using dapagliflozin. Vaginal pruritus and tenderness, vulvovaginal erythema, dyspareunia, dysuria, and vaginal discharge are common symptoms. In this case, severe pruritus with erythema at the vulvovaginal area indicated the occurrence of VV. A study analyzing 12 clinical trials involving 4545 patients with T2DM summarized that once-daily treatment regimens of 2.5 mg, 5 mg, or 10 mg dapagliflozin accompanied an increased risk of VV or balanitis related to the induction of glucosuria. Most of them resolved spontaneously or
after standard antimicrobial therapy; the infections rarely required discontinuation of treatment. Urinary glucose appears to be a risk factor for the development of genital infection; however, the amount of urinary glucose does not necessarily correlate directly with the rates of infection (9). The drug class of SGLT2 inhibitors includes dapagliflozin, canagliflozin, and empagliflozin. It was reported that canagliflozin was associated with an increase in the vaginal colonization of Candida sp. and VV in women with T2DM (10).

Vulvovaginal candidiasis is most frequently caused by Candida albicans, and all diabetic individuals should be treated to prevent further complications (4). Diagnosis must be confirmed by a wet preparation (saline, 10% KOH) or gram stain of the vaginal discharge which shows budding yeasts, hyphens or pseudohyphae, and a positive culture (11). In case of uncontrolled diabetes, VV cannot be treated successfully, entailing a careful re-evaluation of anti-diabetic medications by physicians. SGLT2 inhibitors are usually associated with genital mycotic infections of mild-to-moderate severity, and thus do not necessarily need to be discontinued on the basis of a single VV episode (12). Women with atopic diathesis and type-1 allergies are significantly more prone to vaginal candidiasis than others (13). The clinical symptoms of vaginal candidiasis such as redness and itching suggest an expression of allergy, particularly in recurring cases (14). Its higher frequency in patients with atopy suggests an association between allergy and vaginal candidiasis. Since our patient had a history of atopic dermatitis, we assume that she tends to get VVC more often than the normal population.

Summary
Vulvovaginitis is a frequently encountered acute and recurrent complication of diabetes mellitus, which tends to be exacerbated by poor glycemic control. Appropriate diagnosis and management are essential to provide optimal genital and metabolic health. The analysis of this patient’s history, physical examination, and pathological findings implicates dapagliflozin in the induction of VV. We believe that this case will be highly relevant among atopic patients with potential risk for VVC during usage of these medications. Drug withdrawal may be considered in such patients.

Source of Finance: During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

Conflict of Interest: No conflicts of interest between the authors and/or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

Author Contributions
Concept: Narin Nasıroğlu İmga; Design: Dilek Berker, Data Collection or Processing: Narin Nasıroğlu İmga, Merve Çatak; Analysis or Interpretation: Merve Çatak, Dilek Berker; Literature Search: Narin Nasıroğlu İmga; Writing: Narin Nasıroğlu İmga, Dilek Berker.

References


